Equities Analysts Offer Predictions for DYN Q3 Earnings

Key Points

• HC Wainwright raised their Q3 2025 earnings estimate for Dyne Therapeutics to ($0.73) per share, up from a previous estimate of ($1.06), and maintains a "Buy" rating with a target price of $38.00.
• In the latest quarterly earnings report, Dyne Therapeutics posted ($0.97) EPS, slightly beating the consensus estimate of ($0.99).
• Insider activity showed CEO John Cox purchasing 100,000 shares for $911,000, increasing his position by over 70% and indicating strong confidence in the company's future.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for Dyne Therapeutics in a research report issued on Tuesday, July 29th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.73) per share for the quarter, up from their previous forecast of ($1.06). HC Wainwright currently has a "Buy" rating and a $38.00 target price on the stock. The consensus estimate for Dyne Therapeutics' current full-year earnings is ($3.44) per share. HC Wainwright also issued estimates for Dyne Therapeutics' Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($3.40) EPS, FY2026 earnings at ($3.38) EPS, FY2027 earnings at ($2.23) EPS, FY2028 earnings at ($0.65) EPS and FY2029 earnings at $0.79 EPS.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, topping analysts' consensus estimates of ($0.99) by $0.02.

A number of other equities research analysts also recently commented on the company. Raymond James Financial reiterated an "outperform" rating and issued a $31.00 target price (down from $37.00) on shares of Dyne Therapeutics in a research report on Tuesday. Guggenheim reiterated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, June 18th. Chardan Capital decreased their target price on Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday. Royal Bank Of Canada decreased their target price on Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research report on Tuesday. Finally, Robert W. Baird decreased their target price on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research report on Wednesday, June 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $36.25.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN traded up $0.20 during mid-day trading on Thursday, reaching $10.05. The stock had a trading volume of 2,751,418 shares, compared to its average volume of 2,750,633. The company has a current ratio of 16.83, a quick ratio of 20.35 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.43 billion, a P/E ratio of -2.60 and a beta of 1.08. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $47.45. The business's 50 day moving average price is $10.71 and its 200 day moving average price is $11.48.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox purchased 100,000 shares of Dyne Therapeutics stock in a transaction dated Monday, July 14th. The shares were purchased at an average cost of $9.11 per share, for a total transaction of $911,000.00. Following the completion of the acquisition, the chief executive officer owned 242,179 shares in the company, valued at $2,206,250.69. This represents a 70.33% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 14.14% of the company's stock.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new position in Dyne Therapeutics during the 4th quarter worth $50,000. GAMMA Investing LLC increased its holdings in Dyne Therapeutics by 837.5% during the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock worth $251,000 after purchasing an additional 2,345 shares during the period. CWM LLC increased its holdings in Dyne Therapeutics by 168.1% during the 2nd quarter. CWM LLC now owns 3,030 shares of the company's stock worth $29,000 after purchasing an additional 1,900 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock worth $32,000 after purchasing an additional 2,446 shares during the period. Finally, Quarry LP purchased a new position in Dyne Therapeutics during the 1st quarter worth $47,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.